Cortigent, Inc. (CRGT)
| Market Cap | 65.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.60M |
| Shares Out | 6.50M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CRGT
Cortigent, through its predecessor Second Sight Medical Products, Inc., is a pioneer in developing targeted neurostimulation systems to help patients recover critical body functions. Our technology combines advanced neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Our first commercial system, “Argus II,” was approved by the U.S. Food & Drug Administration under a Humanitarian Device Exemption and has provided artificial vision to hund... [Read more]
Financial Performance
Financial StatementsNews
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
Vivani Medical, Inc. (NASDAQ: VANI), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, today announced the filing of a Registration Statement...
Visual prosthetics developer Cortigent files for a $17 million IPO
Cortigent, a visual prosthetics developer being spun out of Vivani Medical, filed on Monday with the SEC to raise up to $17 million in an initial public offering.
Cortigent IPO Registration Document (S-1)
Cortigent has filed to go public with an IPO on the NASDAQ.